From: 	Sarah Prentice
To:	Publications
Date: 	19 May 2015 10:01
Subject: 	Accepted manuscript
Attachments:	Manuscript_Vaccine Brief Report_Accepted.docx

To whom it may concern,
Here is a copy of the accepted manuscript for a paper in Vaccine. It was accepted on April 24th 2015 and the acceptance letter is below. 

Many thanks
Sarah

>>> Vaccine <jvac@elsevier.com> 24/04/15 9:23 PM >>>
Manuscript Reference No.:  JVAC-D-15-00269R1
Manuscript Title: "The effect of BCG on iron metabolism in the early neonatal period: a controlled trial in Gambian neonates"
Article Type: Brief Report 
Submitted to: Vaccine
Corresponding author: Dr. Sarah Prentice

- - - - - - - - - - - - - - - - - - - - - - - - - - - 

Dear Dr. Sarah  Prentice,

We are pleased to inform you that your above-referenced paper has been accepted for publication in Vaccine.  Congratulations.

Comments on the current version from its peer reviewers (and editor, if indicated) are provided below for your interest and information.

During the remaining steps of the publication process, you will be contacted separately by Elsevier's production department to execute a journal publishing agreement and, when ready, to receive page proofs of your article for error checking and correction by its authors. 

When your paper is published on ScienceDirect, you want to make sure it gets the attention it deserves. To help you get your message across, Elsevier has developed a new, free service called AudioSlides: brief, webcast-style presentations that are shown (publicly available) next to your published article. This format gives you the opportunity to explain your research in your own words and attract interest. You will receive an invitation email to create an AudioSlides presentation shortly. For more information and examples, please visit http://www.elsevier.com/audioslides.

News and embargoes

If you think your article would be interesting for a wider audience, we would be happy to hear from you. Please contact the Journal Manager, John Bailey (jd.bailey@elsevier.com), and we'll send you an information form to complete. Please inform the Journal Manager in the next three days if you are planning publicity for your article through your institution or funding body. Any publicity materials must be approved by Elsevier before release, and must not be distributed before the article has been published.

Uncorrected proofs of articles are published online on ScienceDirect as soon as they are available. As such, information about embargoes is not available. Authors can track the status of their article via the Track Your Accepted Article service.   Uncorrected articles are normally available online within two working days of you receiving the e-mail to download the proofs.

Thank you for submitting your work to Vaccine, dedicated to improving human and animal health by disseminating the findings of immunization science.

Now that you have had your paper accepted for publication in Vaccine, the editors of the journal invite you to 
make your contribution to the vital review process. If you have not yet done so, you can become a 'Reviewer' for Vaccine by contacting the support department at support@elsevier.com

With kind regards,

Robert T Chen, MD MA
Associate Editor
Vaccine

 
- - - - - - - - - - - - - - - - - - - -  
 
COMMENTS OF REVIEWERS (AND EDITOR, if indicated):
 
[If any reviewers of your manuscript provided comments for the authors in a Word® .doc file or other attachment, it may be accessed and downloaded using the following instructions and URL hotlink:

If no instructions and URL hotlink appear above, then no comments were provided by attachment.] 

- - - - - - - - - - - - - - - - - - - -